Adaptation of the stomach to injury from nonsteroidal anti-inflammatory drugs Barbara M. AldermanAndrew S. GiraudNeville D. Yeomans Invited Commentary Pages: 1 - 2
Hepatic fibrosis: Are any of the serum markers useful? Sangik OhNezam H. Afdhal OriginalPaper Pages: 12 - 18
Pharmacologic therapy for portal hypertension Robert C. LoweNorman D. Grace OriginalPaper Pages: 24 - 29
Pegylated interferons: What role will they play in the treatment of chronic hepatitis c? Mitchell L.Shiffman OriginalPaper Pages: 30 - 37
Management of drug-induced liver disease Gustavo MarinoHyman J. ZimmermanJames H. Lewis OriginalPaper Pages: 38 - 48
Should patients with chronic hepatitis c who have normal alt levels be treated? Mark W. RussoRobert S. Brown Jr OriginalPaper Pages: 49 - 53
Treatment of Wilson’s disease: What are the relative roles of penicillamine, trientine, and zinc supplementation? Michael L. Schilsky OriginalPaper Pages: 54 - 59
Primary biliary cirrhosis with features of autoimmune hepatitis Jenny Heathcote OriginalPaper Pages: 60 - 64
Adult-to-adult living donor liver transplantation OlzinAnn T. OlzinskiAmadeo Marcos OriginalPaper Pages: 65 - 70
Extrahepatic manifestations of chronic viral hepatitis Nikolaos T. PyrsopoulosK. Rajender Reddy OriginalPaper Pages: 71 - 78
Kidney disease in patients with chronic hepatitis c Marie PhilipneriBahar Bastani OriginalPaper Pages: 79 - 83
Pegylated interferon plus ribavirin in chronic hepatitis c Bruce R. Bacon Clinical Trials Report Pages: 84 - 84